Cover Image
Market Research Report

Oncology Drug Discovery Services Market, 2017-2030

Published by ROOTS ANALYSIS Product code 518832
Published Content info 270 Pages
Delivery time: 1-2 business days
Price
Back to Top
Oncology Drug Discovery Services Market, 2017-2030
Published: June 21, 2017 Content info: 270 Pages
Description

The early stages of research related to drug discovery, including the identification of a relevant target and a viable lead compound, play a crucial role in the overall success of a drug in preclinical and / or clinical studies. The process of drug discovery is extremely demanding, both in terms of capital expenses and time. Moreover, there is always a high risk of failure associated with R&D programs and, given the increasing regulatory stringency, the approval of new drugs has become significantly complex as well. Over the years, outsourcing has emerged as a popular trend in the pharmaceutical and biotechnology industry, and has demonstrated the potential to effectively cater to the growing demands associated with drug discovery as well. Contract Research Organizations (CROs), with dedicated teams of experts and innovative solutions across the various stages of the drug discovery and development process, are now located in all major global markets. Employing the services of these CROs offers a number of benefits to drug developers, including access to better technologies, latest R&D tools, cost and time savings and the potential to minimize risks associated with the drug discovery process.

Specifically, the oncology market, with an estimated global prevalence of 32 million, imposes a heavy burden on the healthcare system. There exists a significantly high unmet need for novel therapeutic options in this domain, translating into a growing demand for drug discovery initiatives. Therefore, CROs have now emerged as important stakeholders in the oncology market. The increasing trend towards outsourcing has triggered the establishment of several strategic collaborations between drug / therapy developers and CROs. In fact, several CROs have acquired other small / mid-sized CROs or collaborated with them for upgrading their own drug discovery capabilities in an effort to provide integrated services to its clients. Opportunities arising from the growth of personalized medicines, the vast unmet need for therapies for orphan indications, and the adoption of novel technology solutions, such as deep learning solutions, cloud-based technology platforms and 3D cell culture systems, are likely to act as some of the primary drivers of growth within this sector.

Synopsis:

The “Oncology Drug Discovery Services Market, 2017-2030” report features an extensive study of the current market landscape and the future potential of CROs providing drug discovery services in oncology. Cancer, one of the leading causes of death worldwide, is an extremely complex disease and medical science is still struggling to figure out the various factors associated with the disease's origin, propagation, spread (metastasis) and relapse. In fact, in 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer.

With the increasing complexity of drug discovery and development process, the overall spending on R&D in the pharmaceutical / biotechnology sector has increased over the past few years. According to one particular source, this spending has increased from USD 108 billion in 2006 to USD 145 billion in 2016. Heavy investments are being made towards the discovery of novel approaches for the treatment of various types of cancers. The industry is currently under tremendous pressure not only to meet the expectations of a growing patient population but also to identify ways to address the risks associated with novel drug discovery programs. Over the years, CROs offering drug discovery services have contributed significantly and have now grown to become an integral and indispensable part of the pharmaceutical and biotechnology industry.

This study presents an in-depth analysis of a diverse set of companies that offer services across the different steps, such as target identification, target validation, hit generation, hit-to-lead and lead optimization, of the drug discovery process. In addition to other elements, the report features:

  • A discussion on the current state of the market with respect to key players, along with information on the location of headquarters, drug discovery services provided (target identification, target validation, hit generation, hit-to-lead, lead optimization), depth of service portfolio (discovery / preclinical / clinical / commercial manufacturing) and product type (biologics / small molecules).
  • Elaborate profiles of established / emerging players. Each profile features a company overview, financial information, drug discovery service portfolio, recent developments and a view on its future outlook and strategy.
  • An overview of the most active regions in terms of drug discovery services for oncology. The report contains schematic representations of world maps that clearly indicate the location of drug discovery hubs across the world.
  • A comprehensive benchmark analysis, comparing the existing capabilities of various stakeholders within their respective peer groups, to identify ways to become more competitive in the industry. The analysis is based on key parameters such as the depth of service portfolio, the type of molecules researched and the nature of services offered by different companies.
  • An analysis of the agreements that have been established in the recent past, covering drug discovery agreements / research collaborations, license agreements, acquisitions, service alliances and joint venture agreements.
  • A competitive landscape review, featuring a multivariate bubble analysis, based on parameters such as the geographical location, founding year, number of drug discovery services offered and the level of partnering activity in recent years.
  • A discussion on the potential growth areas such as personalized medicines, orphan drugs and complex biopharmaceuticals, and innovative technologies including deep learning solutions and 3D cell culture systems, that are likely to present opportunities or act as growth drivers during the coming years.

In addition, the study features a detailed analysis of the existing market size and the future growth potential of the oncology drug discovery services market for the period 2017-2030. We have provided insights on the likely regional evolution of the market, across North America, Europe, China and the rest of the world. Additionally, we have provided informed estimates of the likely market evolution on the basis of type of product (small molecule, biologics) and key steps of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization). In order to account for the uncertainties associated with some of the key parameters, and to add robustness to our model, we have presented three different forecast scenarios, depicting the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of this study, we invited over 100 stakeholders to participate in a survey, in order to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field.

Example Highlights:

  • 1. During our research, we identified over 115 companies that are actively involved in providing a wide array of oncology drug discovery services; hit-to-lead and lead optimization are amongst the most common services offered by these CROs.
  • 2. Around 25% of the companies offer end-to-end services for drug discovery, starting from target identification till lead optimization. Examples of such one stop shops include (in alphabetical order) Charles River Laboratories, Evotec, GE Healthcare Life Sciences, GenScript, Lonza, PerkinElmer, Syngene, and TCG Lifesciences.
  • 3. The current market is characterized by the presence of several established, as well as emerging CROs. Examples of established players with more than 25 years of overall experience in pharmaceutical sector include AMRI, Aurora Fine Chemicals, Cayman Chemical, ChemDiv, Dalton Pharma Services, DavosPharma, Organix, SRI Biosciences and Syncom. Some of the new players that have recently entered this domain include (in alphabetical order) Abzena, Aurelia Bioscience, Envigo, Enzymlogic, HitGen, INOVOTION, New England Discovery Partners and Tybema BioSolutions.
  • 4. Over 80% of these CROs are located in Europe and North America. It is also worth highlighting that there are several players offering CRO services for oncology drug discovery in certain emerging regions within Asia Pacific, namely India and China. Examples of some of the large-sized CROs based in these locations include (in alphabetical order) Aurigene, GVK Biosciences, Pharmaron, Piramal Pharma Solutions, Sai Life Sciences, ChemPartner and WuXi AppTec.
  • 5. Although the services offered by these companies range from early drug discovery to drug development and commercialization, there are several companies that solely focus on providing drug discovery services. These include (in alphabetical order) Aquila BioMedical, Aris Pharmaceuticals, Attana, Axxam, Beactica, BellBrook Labs, BioDiscovery Group, CanAm Bioresearch, CreaGen Biosciences, Domainex, Evotec, Exiris, Icagen, Organix, Sapient Discovery, Viva Biotech and Zobio.
  • 6. The market has witnessed significant partnering activity in the past three years; several CROs have forged strategic alliances with other services providers in order to expand their drug discovery capabilities. We identified over 70 such collaborations, inked specifically for oncology research. Over 30% of the agreements signed by CROs with other players, including drug / therapy developers or academic players, were focused on co-conducting research for the discovery of either therapeutic targets or lead molecules. Such agreements also involved several big pharma giants, such as (in alphabetical order) AbbVie, AstraZeneca, Daiichi Sankyo, Debiopharm Group, MERCK and Sanofi. Recent examples of acquisitions that we came across include Villapharma's acquisition by Eurofins (January 2017), HD Biosciences' acquisition by Wuxi AppTec (January 2017), Cyprotex's acquisition by Evotec (December 2016) and Blue Stream Laboratories' acquisition by Charles River Laboratories (June 2016).
  • 7. Driven by the rising demand for novel therapeutic targets and drugs, and the growing importance of contract services, we expect the market to continue on its growth trajectory in the foreseen future. We expect the oncology drug discovery services market to grow at an annualized rate of 6.2%, over the period 2017-2030. In terms of geography, majority (more than 70%) of the share is distributed between North America and Europe; other countries, such as China, are likely to grow at a relatively faster rate in the coming decade.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and type of biopharmaceuticals. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2030. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 presents an executive summary of the insights captured in our research. It offers a high level view on the current state of the oncology drug discovery services market, specific factors impacting its growth and how the opportunity is likely to evolve in the mid-long term.

Chapter 3 provides an introduction to the drug discovery approach. It includes details on the time taken for a drug to traverse from the bench to the market, along with a historical account of the evolution of the drug discovery process. It also provides an in-depth explanation of each of the five steps involved in the drug discovery process, including details on associated methods / technologies / approaches. Further, the chapter features a discussion on the key challenges associated with conducting drug discovery research in-house, highlighting the need for contract services providers and the evident shift towards outsourcing drug discovery related operations in oncology.

Chapter 4 includes a comprehensive overview and analysis of the current market landscape of the oncology drug discovery services market. It features an analysis of drug discovery service providers on the basis of their geographical location, type of drug discovery service provided, depth of service portfolio (discovery / preclinical development / clinical development / commercial manufacturing) and the nature of product (small molecule / biologic).

Chapter 5 provides detailed profiles of some of the oncology drug discovery service providers that offer end-to-end services. Each profile features a brief overview of the company, financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

Chapter 6 provides detailed profiles of some of the oncology drug discovery service providers that offer target based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

Chapter 7 provides detailed profiles of some of the oncology drug discovery service providers that offer lead based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

Chapter 8 provides detailed profiles of some of the oncology drug discovery service providers that specialize in lead optimization. Each profile features presents a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

Chapter 9 provides a comprehensive market forecast, depicting how the drug discovery services market for oncology is likely to evolve till 2030. We have presented an analysis of the evolving financial opportunity across various regions, such as North America, Europe, China and ROW. Additionally, we have analyzed the market size based on the nature of molecule (biologic, small molecule) and the key steps of drug discovery (target identification, target validation, hit-to-lead, lead identification and lead optimization). It is worth mentioning that our projections are backed by credible data procured from both secondary and primary sources, and a robust forecast approach validated by in-house and external experts.

Chapter 10 provides a detailed benchmark analysis of the companies that provide drug discovery services in the oncology domain. The key parameters considered for this analysis include the depth of the service portfolio, the type of the molecule and the number of services offered by each company within a peer group (based on geography and employee base). The analysis allows the companies to compare their existing capabilities within their peer group and identify opportunities to become more competitive in the industry.

Chapter 11 features an elaborate discussion and analysis on the collaborations and partnerships that have been recently inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this segment of the overall market. In addition to the aforementioned analysis, the chapter offers an illustrative bubble analysis representing the competitive landscape of players involved in the space, based on their experience, number of drug discovery services offered and the level of activity in terms of collaborations established in the field of oncology research. The key objective of this analysis is to establish a region-wise understanding of contract services offerings and key players involved in the oncology drug discovery market globally.

Chapter 12 highlights important trends that are likely to impact CROs providing drug discovery services and influence their efforts to strengthen their presence in this competitive market. During our research, we identified a number of interesting trends, including focus on personalized medicines, orphan drugs and complex biopharmaceuticals, innovative applications of deep learning, use of 3 D cell culture systems and other novel technologies, which are being developed to reduce the innate complexities associated with drug discovery and optimize the time spent on the overall process. We believe that these trends are likely to significantly influence the industry's evolution over the coming decade.

Chapter 13 presents insights from the survey conducted for this study. The participants, who were primarily Directors / CXO level representatives, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.

Chapter 14 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and key trends that are likely to determine how the market is likely to evolve in the mid- and long terms.

Chapter 15 is a collection of interview transcripts of the discussions held with some of the key players in this industry.

Chapters 16 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

Table of Contents
Product Code: RA10085

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Introduction

  • 3.1. Chapter Overview
  • 3.2. Drug Discovery and Development Timeline
  • 3.3. Drug Discovery Process: History and Evolution
  • 3.4. Current Drug Discovery Process
  • 3.5. Drug Discovery Process: Steps Involved
    • 3.5.1 Target Identification: Introduction and Approaches
      • 3.5.1.1. Chemical Proteomic Based Approaches
      • 3.5.1.2. Expression Cloning Techniques
      • 3.5.1.3. In Silico Approach
    • 3.5.2. Target Validation: Introduction and Approaches
      • 3.5.2.1. Pre-genomic Methods
      • 3.5.2.2. Post-genomic Methods
    • 3.5.3. Hit Discovery: Introduction and Approaches
    • 3.5.4. Hit-to-Lead: Introduction and Approaches
    • 3.5.5. Lead Optimization: Introduction and Models
  • 3.6. Challenges Associated With In-House Drug Discovery
  • 3.7. Shift in Trend towards Outsourcing of Drug Discovery Services
  • 3.8. Oncology at the Forefront of Drug Discovery Research

4. Market Overview

  • 4.1. Chapter Overview
  • 4.2. Oncology Drug Discovery CROs: Overall Landscape
    • 4.2.1. Oncology Drug Discovery CROs: Distribution by Geography
    • 4.2.2. Oncology Drug Discovery CROs: Distribution by Type of Company
    • 4.2.3. Oncology Drug Discovery CROs: Distribution by Type of Drug Discovery Step
    • 4.2.4. Oncology Drug Discovery CROs: Distribution by Business Model
    • 4.2.5. Oncology Drug Discovery CROs: Distribution by Depth of Service Portfolio
    • 4.2.6. Oncology Drug Discovery CROs: Distribution by Nature of Molecule

5. CROs: End-to-End Service Providers

  • 5.1. Chapter Overview
  • 5.2. Charles River Laboratories
    • 5.2.1. Company Overview
    • 5.2.2. Key Operations
    • 5.2.3. Financial Performance
    • 5.2.4. Drug Discovery Services
    • 5.2.5. Recent Developments and Future Outlook
  • 5.3. Evotec
    • 5.3.1. Company Overview
    • 5.3.2. Key Operations
    • 5.3.3. Financial Performance
    • 5.3.4. Drug Discovery Services
    • 5.3.5. Recent Developments and Future Outlook
  • 5.4. GE Healthcare Life Sciences
    • 5.4.1. Company Overview
    • 5.4.2. Key Operations
    • 5.4.3. Financial Performance
    • 5.4.4. Drug Discovery Services
    • 5.4.5. Recent Developments and Future Outlook
  • 5.5. GenScript
    • 5.5.1. Company Overview
    • 5.5.2. Key Operations
    • 5.5.3. Financial Performance
    • 5.5.4. Drug Discovery Services
    • 5.5.5. Recent Developments and Future Outlook
  • 5.6. HD Biosciences (A Subsidiary of WuXi AppTec)
    • 5.6.1. Company Overview
    • 5.6.2. Key Operations
    • 5.6.3. Drug Discovery Services
    • 5.6.4. Recent Developments and Future Outlook
  • 5.7. Vichem Chemie
    • 5.7.1. Company Overview
    • 5.7.2. Key Operations
    • 5.7.3. Drug Discovery Services
    • 5.7.4. Recent Developments and Future Outlook

6. CROs: Target Based Service Providers

  • 6.1. Chapter Overview
  • 6.2. Horizon Discovery
    • 6.2.1. Company Overview
    • 6.2.2. Key Operations
    • 6.2.3. Financial Performance
    • 6.2.4. Drug Discovery Services
    • 6.2.5. Recent Developments and Future Outlook
  • 6.3. Mir Lifescience (Division of MIR Group)
    • 6.3.1. Company Overview
    • 6.3.2. Key Operations
    • 6.3.3. Drug Discovery Services
    • 6.3.4. Recent Developments and Future Outlook

7. CROs: Hit / Lead Based Service Providers

  • 7.1. Chapter Overview
  • 7.2. DIVERCHIM
    • 7.2.1. Company Overview
    • 7.2.2. Key Operations
    • 7.2.3. Drug Discovery Services
    • 7.2.4. Recent Developments and Future Outlook
  • 7.3. GVK Biosciences (A Business Division of GVK)
    • 7.3.1. Company Overview
    • 7.3.2. Key Operations
    • 7.3.3. Financial Performance
    • 7.3.4. Drug Discovery Services
    • 7.3.5. Recent Developments and Future Outlook
  • 7.4. NuChem Therapeutics
    • 7.4.1. Company Overview
    • 7.4.2. Key Operations
    • 7.4.3. Drug Discovery Services
    • 7.4.4. Recent Developments and Future Outlook
  • 7.5. Prestwick Chemical (A Subsidiary of Bionomics)
    • 7.5.1. Company Overview
    • 7.5.2. Key Operations
    • 7.5.3. Financial Performance
    • 7.5.4. Drug Discovery Services
    • 7.5.5. Recent Developments and Future Outlook
  • 7.6. Syncom
    • 7.6.1. Company Overview
    • 7.6.2. Key Operations
    • 7.6.3. Drug Discovery Services
    • 7.6.4. Recent Developments and Future Outlook

8. CROs: Lead Optimization Service Providers

  • 8.1. Chapter Overview
  • 8.2. Envigo
    • 8.2.1. Company Overview
    • 8.2.2. Key Operations
    • 8.2.3. Drug Discovery Services
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Onyx Scientific (A Subsidiary of Ipca Laboratories)
    • 8.3.1. Company Overview
    • 8.3.2. Key Operations
    • 8.3.3. Financial Performance
    • 8.3.4. Drug Discovery Services
    • 8.3.5. Recent Developments and Future Outlook

9. Market Sizing and Forecast

  • 9.1. Chapter Overview
  • 9.2. Forecast Methodology
  • 9.3. Oncology Drug Discovery Services Market, 2017-2030 (USD Billion)
  • 9.4. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Region (USD Billion)
    • 9.4.1. Oncology Drug Discovery Services Market: North America (USD Billion)
    • 9.4.2. Oncology Drug Discovery Services Market: Europe (USD Billion)
    • 9.4.3. Oncology Drug Discovery Services Market: China (USD Billion)
    • 9.4.4. Oncology Drug Discovery Services Market: Rest of the World (USD Billion)
  • 9.5. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule (USD Billion)
  • 9.6. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service (USD Billion)

10. Benchmark Analysis

  • 10.1. Chapter Overview
  • 10.2. Benchmark Analysis: Methodology
  • 10.3. Benchmark Analysis: Peer Groups
    • 10.3.1. Benchmark Analysis: North America, Peer Group I
    • 10.3.2. Benchmark Analysis: North America, Peer Group II
    • 10.3.3. Benchmark Analysis: North America, Peer Group III
    • 10.3.4. Benchmark Analysis: Europe, Peer Group IV
    • 10.3.5. Benchmark Analysis: Europe, Peer Group V
    • 10.3.6. Benchmark Analysis: Europe, Peer Group VI
    • 10.3.7. Benchmark Analysis: Asia Pacific, Peer Group VII

11. Recent Collaborations

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. Oncology Drug Discovery Service Providers: Recent Collaborations
    • 11.3.1. Oncology Drug Discovery Partnerships: Cumulative Trend, 2014 - H1 2017
    • 11.3.2. Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
    • 11.3.3. Oncology Drug Discovery Partnerships: Most Active Players
    • 11.3.4. Oncology Drug Discovery Partnerships: Analysis by Experience, Number of Services and Activity

12. Future Growth Opportunities

  • 12.1. Chapter Overview
  • 12.2. Oncology Drug Discovery is on the Cutting Edge of Personalized Medicine
  • 12.3. Growing Popularity of Biologics Demands Specialized Research Expertise
  • 12.4. Orphan Cancer Indications Offer New Opportunities for CROs
  • 12.5. Start-ups in Oncology Will Continue to Seek Increased Support of CROs
  • 12.6. Technological Advancements to Cater to Complexities Associated with the Drug Discovery Process
    • 12.6.1. Deep Learning Technology
    • 12.6.2. Organoids and 3D Cell Culture Systems
    • 12.6.3. Acoustic Droplet Ejection (ADE) Technology
    • 12.6.4. CRISPR-Cas9 Gene Editing Technology
    • 12.6.5. Cloud Based Technology Platforms

13. Survey Analysis

  • 13.1. Chapter Overview
  • 13.2. Seniority Level of Respondents
  • 13.3. Type of Drug Discovery Service
  • 13.4. Nature of Molecule
  • 13.5. Depth of Service Portfolio
  • 13.6. Likely Market Size
  • 13.7. Likely Growth Rate

14. Conclusion

  • 14.1. Outsourcing has Emerged as a Convenient Option for Drug Discovery and Early Stage Development
  • 14.2. Currently, Europe Stands out as the Major Hub for CROs, followed by North America and Asia Pacific
  • 14.3. Lead Generation and Lead Optimization are the Most Frequently Outsourced Operations
  • 14.4. Flexible Partnership Models have Fostered Collaborations between Drug Developers and CROs
  • 14.5. Innovative Technologies and Untapped Opportunity Areas are Anticipated to Drive Long-Term Growth
  • 14.6. Driven by the growing demand for contract services, the market is expected to witness continuous growth in the foreseen future

15. Interview Transcripts

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

List of Figures:

  • Figure 3.1: Drug Discovery and Development Timeline
  • Figure 3.2: Drug Discovery Process: History and Evolution
  • Figure 3.3: Drug Target: Primary Criteria for Successful Identification
  • Figure 3.4: Drug Discovery Services: Advantages of Outsourcing
  • Figure 4.1: Oncology Drug Discovery CROs: Distribution by Geography
  • Figure 4.2: Oncology Drug Discovery CROs: Distribution by Country
  • Figure 4.3: Oncology Drug Discovery CROs: Distribution by Type of Company
  • Figure 4.4: Oncology Drug Discovery CROs: Distribution by Type of Drug Discovery Step
  • Figure 4.5: Oncology Drug Discovery CROs: Distribution by Business Model
  • Figure 4.6: Oncology Drug Discovery CROs: Distribution by Depth of Service Portfolio
  • Figure 4.7: Oncology Drug Discovery CROs: Distribution by Type of Molecule
  • Figure 5.1: Charles River Laboratories: Business Segments
  • Figure 5.2: Charles River Laboratories: Key Operations
  • Figure 5.3: Charles River Laboratories: Revenues, 2012-2016 (USD Billion)
  • Figure 5.4: Charles River Laboratories: Revenues by Business Divisions, 2016 (USD Million)
  • Figure 5.5: Evotec: Key Operations
  • Figure 5.6: Evotec: Revenues, 2013-Q1 2017 (EUR Million)
  • Figure 5.7: Evotec: Revenues by Business Divisions, 2016 (EUR Million)
  • Figure 5.8: Evotec: Drug Discovery Services
  • Figure 5.9: GE Healthcare Life Sciences: Key Operations
  • Figure 5.10: GE Healthcare: Revenues, 2012-2016 (USD Billion)
  • Figure 5.11: GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
  • Figure 5.12: GE Healthcare: Drug Discovery Technologies
  • Figure 5.13: GE Healthcare: Cancer Research Tools Used for Drug Discovery Steps
  • Figure 5.14: GenScript: Business Units
  • Figure 5.15: GenScript: Key Operations
  • Figure 5.16: GenScript: Revenues, 2012-2016 (USD Million)
  • Figure 5.17: GenScript: Revenues by Business Divisions, 2016 (USD Million)
  • Figure 5.18: GenScript: Drug Discovery Services
  • Figure 5.19: HD Biosciences: Key Operations
  • Figure 5.20: HD Biosciences: Drug Discovery Services
  • Figure 5.21: Vichem Chemie: Key Operations
  • Figure 6.1: Horizon Discovery: Key Operations
  • Figure 6.2: Horizon Discovery: Revenues, 2012-2016 (GBP Million)
  • Figure 6.3: Horizon Discovery: Revenues by Business Segments, 2016 (GBP Million)
  • Figure 6.4: Mir Lifescience: Key Operations
  • Figure 7.1: DIVERCHIM: Key Operations
  • Figure 7.2: DIVERCHIM: Drug Discovery Services
  • Figure 7.3: GVK Biosciences: Key Operations
  • Figure 7.4: GVK: Revenues, 2012-2016 (INR Billion)
  • Figure 7.5: NuChem Therapeutics: Key Operations
  • Figure 7.6: NuChem Therapeutics: Drug Discovery Services
  • Figure 7.7: Prestwick Chemical: Key Operations
  • Figure 7.8: Bionomics: Revenues, 2012-2016 (USD Million)
  • Figure 7.9: Syncom: Key Operations
  • Figure 8.1: Envigo: Key Operations
  • Figure 8.2: Onyx Scientific: Key Operations
  • Figure 8.3: Onyx Scientific: Revenues, 2012-2016 (INR Million)
  • Figure 9.1: Oncology Drug Discovery Services Market, 2017-2030: Base Scenario (USD Billion)
  • Figure 9.2: Oncology Drug Discovery Services Market, 2017, 2025 and 2030: Distribution by Region
  • Figure 9.3: Oncology Drug Discovery Services Market, 2017-2030: North America, Base Scenario (USD Billion)
  • Figure 9.4: Oncology Drug Discovery Services Market, 2017-2030: Europe, Base Scenario (USD Billion)
  • Figure 9.5: Oncology Drug Discovery Services Market, 2017-2030: China, Base Scenario (USD Billion)
  • Figure 9.6: Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Base Scenario (USD Billion)
  • Figure 9.7: Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Base Scenario (USD Billion)
  • Figure 9.8: Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Base Scenario (USD Billion)
  • Figure 10.1: Benchmark Analysis: Distribution by Company Size (Number of Employees)
  • Figure 10.2: Benchmark Analysis: North America, Peer Group I
  • Figure 10.3: Benchmark Analysis: North America, Peer Group II
  • Figure 10.4: Benchmark Analysis: North America, Peer Group III
  • Figure 10.5: Benchmark Analysis: Europe, Peer Group IV
  • Figure 10.6: Benchmark Analysis: Europe, Peer Group V
  • Figure 10.7: Benchmark Analysis: Europe, Peer Group VI
  • Figure 10.8: Benchmark Analysis: Asia Pacific, Peer Group VII
  • Figure 11.1: Oncology Drug Discovery Partnerships: Cumulative Trend, 2014 - H1 2017
  • Figure 11.2: Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
  • Figure 11.3: Oncology Drug Discovery Partnerships: Most Active Players
  • Figure 11.4: Oncology Drug Discovery Service Providers: 3-Dimensional Analysis based on Experience, Number of Services and Recent Collaborations (North America)
  • Figure 11.5: Oncology Drug Discovery Service Providers: 3-Dimensional Analysis based on Experience, Number of Services and Recent Collaborations (Europe)
  • Figure 11.6: Oncology Drug Discovery Service Providers: 3-Dimensional Analysis based on Experience, Number of Services and Recent Collaborations (Asia)
  • Figure 12.1: Oncology Drug Discovery Services: Future Growth Opportunities
  • Figure 13.1: Survey Analysis: Distribution by Geography
  • Figure 13.2: Survey Analysis: Seniority Levels of Respondents
  • Figure 13.3: Survey Analysis: Distribution by Type of Drug Discovery Service
  • Figure 13.4: Survey Analysis: Distribution by Nature of Molecule
  • Figure 13.5: Survey Analysis: Distribution by Depth of Service Portfolio
  • Figure 13.6: Survey Analysis: Likely Current Market Size
  • Figure 13.7: Survey Analysis: Likely Growth Rate
  • Figure 14.1: Oncology Drug Discovery Services Market, 2017, 2022 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List of Tables:

  • Table 3.1: Drug Target Classification
  • Table 4.1: Oncology Drug Discovery Service Providers: Details on Geography and Type of Drug Discovery Service
  • Table 4.2: Oncology Drug Discovery Service Providers: Details on Type of CRO, Depth of Service Portfolio and Nature of Molecule
  • Table 5.1: Oncology Drug Discovery: End-to-End Service Providers
  • Table 6.1: Oncology Drug Discovery: Target Based Service Providers
  • Table 7.1: Oncology Drug Discovery: Hit / Lead Based Service Providers
  • Table 8.1: Oncology Drug Discovery: Lead Optimization Service Providers
  • Table 10.1: Benchmark Analysis: Peer Groups
  • Table 11.1: Oncology Drug Discovery Services: Recent Collaborations
  • Table 13.1: Survey Response: Overview of the Participating Companies
  • Table 13.2: Survey Response: Seniority Level of Respondents
  • Table 13.3: Survey Response: Type of Drug Discovery Service
  • Table 13.4: Survey Response: Nature of Molecule
  • Table 13.5: Survey Response: Depth of Service Portfolio
  • Table 13.6: Survey Response: Likely Current Market Size
  • Table 13.7: Survey Response: Likely Growth Rate
  • Table 16.1: Oncology Drug Discovery CROs: Distribution by Country
  • Table 16.2: Oncology Drug Discovery CROs: Distribution by Type of Company
  • Table 16.3: Oncology Drug Discovery CROs: Distribution by Type of Drug Discovery Step
  • Table 16.4: Oncology Drug Discovery CROs: Distribution by Business Model
  • Table 16.5: Oncology Drug Discovery CROs: Distribution by Depth of Service Portfolio
  • Table 16.6: Oncology Drug Discovery CROs: Distribution by Nature of Molecule
  • Table 16.7: Charles River Laboratories: Revenues, 2012-2016 (USD Billion)
  • Table 16.8: Charles River Laboratories: Revenues by Business Divisions, 2016 (USD Million)
  • Table 16.9: Evotec: Revenues, 2013-Q1 2017 (EUR Million)
  • Table 16.10: Evotec: Revenues by Business Divisions, 2016 (EUR Million)
  • Table 16.11: GE Healthcare: Revenues, 2012 - 2016 (USD Billion)
  • Table 16.12: GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
  • Table 16.13: GenScript: Revenues, 2012 - 2016 (USD Million)
  • Table 16.14: GenScript: Revenues by Business Divisions, 2016 (USD Million)
  • Table 16.15: Horizon Discovery: Revenues, 2012 - 2016 (GBP Million)
  • Table 16.16: Horizon Discovery: Revenues by Business Segments, 2016 (GBP Million)
  • Table 16.17: GVK: Revenues, 2012-2016 (INR Billion)
  • Table 16.18: Bionomics: Revenues, 2012-2016 (USD Million)
  • Table 16.19: Onyx Scientific: Revenues, 2012-2016 (INR Million)
  • Table 16.20: Oncology Drug Discovery Services Market, 2017-2030: Conservative Scenario (USD Billion)
  • Table 16.21: Oncology Drug Discovery Services Market, 2017-2030: Base Scenario (USD Billion)
  • Table 16.22: Oncology Drug Discovery Services Market, 2017-2030: Optimistic Scenario (USD Billion)
  • Table 16.23: Oncology Drug Discovery Services Market, 2017, 2025 and 2030: Distribution by Region (%)
  • Table 16.24: Oncology Drug Discovery Services Market, 2017-2030: North America, Conservative Scenario (USD Billion)
  • Table 16.25: Oncology Drug Discovery Services Market, 2017-2030: North America, Base Scenario (USD Billion)
  • Table 16.26: Oncology Drug Discovery Services Market, 2017-2030: North America, Optimistic Scenario (USD Billion)
  • Table 16.27: Oncology Drug Discovery Services Market, 2017-2030: Europe, Conservative Scenario (USD Billion)
  • Table 16.28: Oncology Drug Discovery Services Market, 2017-2030: Europe, Base Scenario (USD Billion)
  • Table 16.29: Oncology Drug Discovery Services Market, 2017-2030: Europe, Optimistic Scenario (USD Billion)
  • Table 16.30: Oncology Drug Discovery Services Market, 2017-2030: China, Conservative Scenario (USD Billion)
  • Table 16.31: Oncology Drug Discovery Services Market, 2017-2030: China, Base Scenario (USD Billion)
  • Table 16.32: Oncology Drug Discovery Services Market, 2017-2030: China, Optimistic Scenario (USD Billion)
  • Table 16.33: Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Conservative Scenario (USD Billion)
  • Table 16.34: Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Base Scenario (USD Billion)
  • Table 16.35: Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Optimistic Scenario (USD Billion)
  • Table 16.36: Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Conservative Scenario (USD Billion)
  • Table 16.37: Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Base Scenario (USD Billion)
  • Table 16.38: Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Optimistic Scenario (USD Billion)
  • Table 16.39: Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Conservative Scenario (USD Billion)
  • Table 16.40: Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Base Scenario (USD Billion)
  • Table 16.41: Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Optimistic Scenario (USD Billion)
  • Table 16.42: Benchmark Analysis: Distribution by Company Size (Number of Employees)
  • Table 16.43: Oncology Drug Discovery Partnerships: Cumulative Trends
  • Table 16.44: Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
  • Table 16.45: Oncology Drug Discovery Partnerships: Most Active Players
  • Table 16.46: Survey Analysis: Distribution by Geography
  • Table 16.47: Survey Analysis: Seniority Levels of Respondents
  • Table 16.48: Survey Analysis: Distribution by Type of Drug Discovery Service
  • Table 16.49: Survey Analysis: Distribution by Nature of Molecule
  • Table 16.50: Survey Analysis: Distribution by Depth of Service Portfolio
  • Table 16.51: Survey Analysis: Likely Current Market Size
  • Table 16.52: Survey Analysis: Likely Growth Rate
  • Table 16.53: Oncology Drug Discovery Services Market, 2017, 2022 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Listed Companies:

The following companies and organizations have been mentioned in the report:

  • 1. AbbVie
  • 2. Abzena
  • 3. Academic Medical Center Helsinki
  • 4. Actelion Pharmaceuticals
  • 5. ActivX Biosciences
  • 6. Addex Therapeutics
  • 7. Advinus Therapeutics
  • 8. Agilux Laboratories
  • 9. Agios Pharmaceuticals
  • 10. Albany Molecular Research
  • 11. AlphaGene
  • 12. AmorChem
  • 13. AnCoreX Therapeutics
  • 14. Anthem Biosciences
  • 15. APEIRON Biologics
  • 16. Aptuit
  • 17. Aquila BioMedical
  • 18. Aragen Bioscience
  • 19. Aris Pharmaceuticals
  • 20. ArQule
  • 21. Asahi Kasei Pharma
  • 22. Asclepia MedChem Solutions
  • 23. AsisChem
  • 24. Astex Therapeutics
  • 25. AstraZeneca
  • 26. Attana
  • 27. Aurelia Bioscience
  • 28. Aurigene
  • 29. Aurora Fine Chemicals
  • 30. Avvinity
  • 31. Axon Biochemicals
  • 32. Axon Medchem
  • 33. Axxam
  • 34. Babraham Institute
  • 35. Bayer Group
  • 36. Beactica
  • 37. BellBrook Labs
  • 38. Beryllium Discovery
  • 39. Bienta
  • 40. Biobide
  • 41. Biocon
  • 42. BioDiscovery Group
  • 43. BioDuro
  • 44. BioFocus DPI
  • 45. Biomedicum Genomics
  • 46. BioMotiv
  • 47. Bionaturis Group
  • 48. Bionomics
  • 49. BioNTech
  • 50. BioStructures
  • 51. Birkbeck College
  • 52. Blue Stream Laboratories
  • 53. British Columbia Cancer Agency
  • 54. C4X Discovery
  • 55. Cadiz University
  • 56. California Institute for Biomedical Research
  • 57. Caliper Life Sciences
  • 58. CanAm Bioresearch
  • 59. Cancer Research Technology
  • 60. Cancer Research UK
  • 61. Carrick Therapeutics
  • 62. Cayman Chemical
  • 63. Celgene
  • 64. Celsis Group
  • 65. Centauri Therapeutics
  • 66. Centro Nacional de Investigaciones Oncológicas
  • 67. Charles River Laboratories
  • 68. Charnwood Molecular
  • 69. ChemBridge
  • 70. ChemDiv
  • 71. ChemoGenics BioPharma
  • 72. Chemveda Life Sciences
  • 73. Child Health and Development Institute of Connection
  • 74. Clininvent
  • 75. CombinatoRx
  • 76. Confluence Discovery Technologies
  • 77. Covance
  • 78. CreaGen Biosciences
  • 79. CRELUX
  • 80. CrownBio
  • 81. Curadev Pharma
  • 82. Curis
  • 83. Cyprotex
  • 84. Dabur Group
  • 85. Dabur Research Foundation
  • 86. Daiichi Sankyo
  • 87. Dalton Pharma Services
  • 88. Dana-Farber Cancer Institute
  • 89. DavosPharma
  • 90. Debiopharm Group
  • 91. DIVERCHIM
  • 92. Domainex
  • 93. Dong-A ST
  • 94. Dr. Reddy's Laboratories
  • 95. École Polytechnique Fédérale de Lausanne
  • 96. EDELRIS
  • 97. Enamine
  • 98. Envigo
  • 99. Enzymlogic
  • 100. Epichem
  • 101. Epistem
  • 102. Eurofins Scientific
  • 103. Evotec
  • 104. Exiris
  • 105. Exquiron Biotech
  • 106. Exscientia
  • 107. Fannin Innovation Studio
  • 108. Felicitex Therapeutics
  • 109. FORMA Therapeutics
  • 110. Free University of Amsterdam
  • 111. Fusion Antibodies
  • 112. Galapagos
  • 113. GalChimia
  • 114. Galectin Therapeutics
  • 115. GE Healthcare Life Sciences
  • 116. Genentech
  • 117. Genomics Medicine Ireland
  • 118. GenScript
  • 119. GL Chemtec International
  • 120. GlaxoSmithKline
  • 121. Griffith University
  • 122. GVK Biosciences
  • 123. H3 Biomedicine
  • 124. Harlan Laboratories
  • 125. HD Biosciences
  • 126. Helmholtz Association
  • 127. HitGen
  • 128. Horizon Discovery
  • 129. HQL Pharmaceuticals
  • 130. Huntingdon Life Sciences
  • 131. Icagen
  • 132. iGEM
  • 133. Infinity Pharmaceuticals
  • 134. INOVOTION
  • 135. Inserm
  • 136. Insilico Medicine
  • 137. Institut du cancer de Montréal
  • 138. Institute for Research in Immunology and Cancer Commercialization of Research
  • 139. Institute of Cancer Research, London
  • 140. INTEGREX Research
  • 141. IntelliSyn
  • 142. IOTA Pharmaceuticals
  • 143. Ipca Laboratories
  • 144. Jagiellonian University
  • 145. Janssen Biotech
  • 146. Janssen Pharmaceuticals
  • 147. Jinan Nornoon Biological Engineering
  • 148. Johnson & Johnson
  • 149. Joseph Fourier University
  • 150. JPT Peptide Technologies
  • 151. Jubilant Biosys
  • 152. Jubilant Life Sciences
  • 153. Juniper Pharma Services
  • 154. Juno Therapeutics
  • 155. KYORIN Pharmaceutical
  • 156. LabCorp
  • 157. Lead Discovery Center
  • 158. Leiden University
  • 159. Longthera Pharmaceuticals
  • 160. Lonza
  • 161. Marshall University
  • 162. Mascot Industries
  • 163. Max Planck Innovation
  • 164. Max Planck Institute of Biochemistry
  • 165. Medicilon
  • 166. Medivir
  • 167. Memorial Sloan Kettering Cancer Center
  • 168. Mercachem
  • 169. Merck Serono
  • 170. Merck Sharpe & Dohme
  • 171. Mir Lifescience
  • 172. Mirimus
  • 173. Moderna Therapeutics
  • 174. n3D Biosciences
  • 175. Nanjing Biotech Innovation Corporation
  • 176. Nanjing Legend Biotechnology
  • 177. Nanosyn
  • 178. National Cancer Institute
  • 179. National Resource Center for Mutant Mice
  • 180. National University of Singapore
  • 181. NEOMED Institute
  • 182. New England Discovery Partners
  • 183. Nile Scan & Labs
  • 184. Nimbus Therapeutics
  • 185. NovAliX
  • 186. NuChem Therapeutics
  • 187. OcellO
  • 188. Oncompass Medicine
  • 189. Oncotest
  • 190. Oncotyrol
  • 191. Ontario Institute for Cancer Research
  • 192. Onyx Scientific
  • 193. Organix
  • 194. OriBase Pharma
  • 195. Orion Corporation
  • 196. OTAVAchemicals
  • 197. OXELTIS
  • 198. Oxford Bioscience Partners
  • 199. Oxford University
  • 200. Paraza Pharma
  • 201. Paterson Institute for Cancer Research
  • 202. Pepscan
  • 203. PerkinElmer
  • 204. Pfizer
  • 205. Pharmaceutical Product Development
  • 206. PharmAgra Labs
  • 207. Pharmaron
  • 208. Pharminox
  • 209. PHENOMIN-ICS
  • 210. Piramal Pharma Solutions
  • 211. Prestwick Chemical
  • 212. Proteros
  • 213. Provid Pharmaceuticals
  • 214. Queen's University Belfast
  • 215. Quotient Bioresearch
  • 216. Qurient
  • 217. Radboud University
  • 218. Ratnamani Healthcare
  • 219. Reach Separations
  • 220. Red Glead Discovery
  • 221. Redx Pharma
  • 222. Regen BioPharma
  • 223. Roche
  • 224. RTI International
  • 225. Sage Laboratories
  • 226. Sai Life Sciences
  • 227. SAMDI Tech
  • 228. Sanofi
  • 229. Sapient Discovery
  • 230. SARomics Biostructures
  • 231. SBH Sciences
  • 232. Schrödinger
  • 233. Selcia
  • 234. Selvita
  • 235. Semmelweis University
  • 236. Shanghai ChemPartner
  • 237. ShangPharma
  • 238. Shionogi
  • 239. SRI Biosciences
  • 240. Stanford University
  • 241. Sundia MediTech
  • 242. Sygnature Discovery
  • 243. Syncom Healthcare
  • 244. Syngene
  • 245. Synvolux Therapeutics
  • 246. Taros Chemicals
  • 247. TATA Group
  • 248. Tata Trusts
  • 249. TC Scientific
  • 250. TCG Lifesciences
  • 251. The Agency for Science, Technology and Research
  • 252. The Eskitis Institute for Drug Discovery
  • 253. The European Molecular Biology Laboratory
  • 254. The Milner Therapeutics Institute
  • 255. The Ohio State University Comprehensive Cancer Center
  • 256. The Rockefeller University
  • 257. The Scripps Research Institute
  • 258. The University Medical Center Groningen
  • 259. The University of Texas MD Anderson Cancer Center
  • 260. The Wellcome Trust Sanger Institute
  • 261. Thermo Fisher Scientific
  • 262. Translational Drug Development
  • 263. Translational Genomics Research Institute
  • 264. Tri-Institutional Therapeutics Discovery Institute
  • 265. Tybema BioSolutions
  • 266. UbiQ
  • 267. Ubiquigent
  • 268. UCB Biopharma
  • 269. United BioPharma
  • 270. Univalor
  • 271. University College London
  • 272. University of California, Berkeley
  • 273. University of Cambridge
  • 274. University of Montreal
  • 275. University of Strasbourg
  • 276. University of Tsukuba
  • 277. University of Wisconsin-Madison: School of Pharmacy
  • 278. Vanta Bioscience
  • 279. Vichem Chemie
  • 280. Villapharma Research
  • 281. ViroStatics
  • 282. Viva Biotech
  • 283. Wageningen University
  • 284. Weill Cornell Medicine
  • 285. WIL Research
  • 286. WuXi AppTec
  • 287. York University
  • 288. Zenith Technologies
  • 289. ZoBio
Back to Top